TA
CTIC

Tiedemann Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Tiedemann Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-73,129
Closed -$196K – 278
2017
Q4 		$196K Buy
+73,129
New +$214K 0.02% 214
2017
Q3 		– Sell
-73,129
Closed -$242K – 492
2017
Q2 		$242K Buy
73,129
+39,698
+119% +$154K 0.02% 393
2017
Q1 		$140K Hold
33,431
– – 0.01% 379
2016
Q4 		$136K Buy
+33,431
New +$139K 0.01% 308

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tiedemann Advisors's CTIC Position: Q1 2018 in Review

Tiedemann Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2018, closing a stake of 73,129 shares — an estimated $196K sold.

Tiedemann Advisors first reported a position in CTIC in Q4 2016 and held it in 4 quarters. The position peaked at $242K in Q2 2017. 67 funds tracked by Wall St. Rank hold CTIC as of Q1 2018.

  • Tiedemann Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2018 after selling out during the quarter.
  • Tiedemann Advisors sold 73,129 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2018, an estimated $196K.
  • Tiedemann Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2016 and held it in 4 quarters.
  • Tiedemann Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $242K in Q2 2017.
  • 67 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2018.

Based on Tiedemann Advisors's 13F filing for Q1 2018, filed 11 May 2018.